Study protocol: Hybrid Type I cost-effectiveness and implementation study of interpersonal psychotherapy (IPT) for men and women prisoners with major depression

详细信息    查看全文

• 作者：Jennifer E. Johnson^a ; ^{Jennifer.Johnson@hc.msu.edu" class="auth_mail" title="E-mail the corresponding author} ; Ted R. Miller^b ; ^{miller@pire.org" class="auth_mail" title="E-mail the corresponding author} ; Robert L. Stout^c ; ^{Stout@pire.org" class="auth_mail" title="E-mail the corresponding author} ; Caron Zlotnick^d ; ^{Caron_Zlotnick@brown.edu" class="auth_mail" title="E-mail the corresponding author} ; Louis A. Cerbo^e ; ^{Louis.Cerbo@doc.ri.gov" class="auth_mail" title="E-mail the corresponding author} ; Joel T. Andrade^f ; ^{jandrade@mhm-services.com" class="auth_mail" title="E-mail the corresponding author} ; Shannon Wiltsey-Stirman^g ; ^{Shannon.Wiltsey-Stirman@va.gov" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Prisoners ; Prisons ; Major depressive disorder ; Implementation science ; Cost-effectiveness
• 刊名：Contemporary Clinical Trials
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：47
• 期：Complete
• 页码：266-274
• 全文大小：367 K

文摘

This article describes the protocol for a Hybrid Type I cost-effectiveness and implementation study of interpersonal psychotherapy (IPT) for men and women prisoners with major depressive disorder (MDD). The goal is to promote uptake of evidence-based treatments in criminal justice settings by conducting a randomized effectiveness study that collects implementation data, including a full cost-effectiveness analysis.

Background

More than 2.3 million people are incarcerated in the United States on any given day. MDD is the most common severe mental illness among incarcerated individuals. Despite the prevalence and consequences of MDD among incarcerated populations, this study will be the first fully-powered randomized trial of any treatment for MDD in an incarcerated population.

Design

Given the politically charged nature of the justice system, advantageous health outcomes are often not enough to get an intervention implemented in prisons. To increase the policy impact of this trial, we sought advice from prison providers and administrators about outcomes that would be persuasive to policy-makers and defensible to the public. In this trial, effectiveness questions will be answered using a randomized clinical trial design comparing IPT plus prison treatment as usual (TAU) to TAU alone, with outcomes including depressive symptoms (primary), suicidality, and in prison functioning (enrollment and completion of correctional programs; disciplinary and incident reports; aggression/victimization; social support). Implementation outcomes will include cost-effectiveness; feasibility and acceptability of IPT to clients, providers, and administrators; prison provider intervention fidelity, attitudes, and competencies; and barriers and facilitators of implementation assessed through surveys, interviews, and process notes.